EP276/#774 Optimal cytoreduction and platinum-free interval affecting the duration of bevacizumab-based maintenance therapy and prognosis in the first platinum-sensitive recurrence of ovarian cancer. (4th December 2022)

• Record Type: Journal Article
• Authors: Oh, Soohyun; Park, Soo Jin; Park, Min Young; Kim, Jae-Weon; Park, Noh Hyun; Lee, Seungho; Kim, Hee Seung
• Is Part Of: International journal of gynecological cancer. Volume 32(2022)Supplement 3
• Page Start: A163
• Page End: A165
• Publication Date: 2022-12-04
• Subjects: Generative organs, Female -- Cancer -- Periodicals; 616.99465
• DOI: 10.1136/ijgc-2022-igcs.367
• Languages: English
• ISSNs: 1048-891X

Abstract

Abstract : Objectives: Even though bevacizumab-based maintenance therapy (BMT) reportedly improved overall survival in the first platinum-sensitive recurrence of ovarian cancer, there was a lack of factors for predicting how long it will last. Thus, we investigated factors affecting the duration of BMT and their effect on the prognosis of the disease. Methods: We included patients diagnosed with the first platinum-sensitive recurrence of ovarian cancer in two tertiary centers from January 2015 till August 2021. All patients received six cycles of paclitaxel-carboplatin-bevacizumab followed by BMT. We retrospectively collected data such as age, histologic type, status of BRCA mutation, platinum-free interval (PFI), extent of secondary cytoreduction, presence of extra-abdominal disease, number of recur lesions, duration of BMT, progression-free survival (PFS) and cancer-specific survival after the first recurrence (CSS). Results: A total of 103 patients were included, and the median cycles of BMT was 13 (range, 1–108). Among them, 25 (24.3%) underwent optimal cytoreduction, whereas 4 (3.9%) and 74 (71.8%) received suboptimal cytoreduction or no surgery. PFI >12 months and optimal cytoreduction were factors for predicting 13 or more cycles of BMT (adjusted odds ratios, 3.334 and 4.675; 95% confidence intervals [CIs], 1.253–8.869 and 1.242–17.601), and improving CSS (adjusted hazard ratios [HRs], 0.064 and 0.121; 95% CIs, 0.011–0.355 and 0.181–0.837). Additionally, PFI >12 months was associated with better PFS (adjusted HR, 0.489; 95% CIs, 0.291–0.822). Conclusions: PFI >12 months and optimal cytoreduction potentially predicted 13 or more cycles of BMT and were related to improved survival in the first platinum-sensitive recurrence of ovarian cancer.